Multiple Myeloma Clinical Trial
— LINKER-MM4Official title:
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM. This study consists of 2 phases: - In Phase 1, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2. - In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the ability of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM. The study is looking at several research questions, including: - What side effects may happen from taking linvoseltamab? - What the right dosing regimen is for linvoseltamab? - How many participants treated with linvoseltamab have improvement of their disease and for how long? - The effects of linvoseltamab study treatment before and after transplant - How much linvoseltamab is in the blood at different times? - Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).
Status | Recruiting |
Enrollment | 132 |
Est. completion date | November 2, 2035 |
Est. primary completion date | November 2, 2035 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 2. Confirmed diagnosis of symptomatic multiple myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria 3. Measurable disease, according to the 2016 IMWG response criteria, as defined in the protocol 4. No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol 5. Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol 6. Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance. Key Exclusion Criteria: 1. Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis 2. Known central nervous system (CNS) involvement with MM, known or suspected progressive multifocal leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment 3. Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy 4. Diagnosis of non-secretory MM, active plasma cell leukemia, primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) Note: Other protocol-defined Inclusion/Exclusion criteria apply |
Country | Name | City | State |
---|---|---|---|
France | CHU De Lille | Lille | |
France | Hopital Universitaire Necker Enfants Malades | Paris | |
United States | Atrium Health Levine Cancer | Charlotte | North Carolina |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | MD Anderson Cancer Centre | Houston | Texas |
United States | University of California | Los Angeles | California |
United States | Norton Healthcare, Inc. | Louisville | Kentucky |
United States | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | NYU Langone Health | New York | New York |
United States | UCI Health | Orange | California |
Lead Sponsor | Collaborator |
---|---|
Regeneron Pharmaceuticals |
United States, France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of dose-limiting toxicities (DLTs) | Phase 1 | End of the Observation period; up to day 28 | |
Primary | Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Post-Last Linvoseltamab Dose, up to 90 days | |
Primary | Severity of TEAEs | Phase 1 | Post-Last Linvoseltamab Dose, up to 90 days | |
Primary | Incidence of adverse events of special interest (AESIs) | Phase 1 | Post-Last Linvoseltamab Dose, up to 90 days | |
Primary | Severity of AESIs | Phase 1 | Post-Last Linvoseltamab Dose, up to 90 days | |
Primary | Proportion of participants with a very good partial response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria | Phase 2 | Up to 5 years | |
Primary | Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy | Phase 2 Transplant-eligible cohort | Up to 5 years | |
Primary | Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy | Phase 2 Transplant-eligible cohort | Up to 5 years | |
Primary | Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II | Phase 2 Transplant-ineligible cohort | Up to 5 years | |
Primary | Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II | Phase 2 Transplant ineligible cohort | Up to 5 years | |
Secondary | Concentrations of Linvoseltamab in serum | Phases 1 and 2 | Post-Last Linvoseltamab Dose, up to 12 weeks | |
Secondary | Concentrations of total soluble B-cell maturation antigen (BCMA) | Phases 1 and 2 | Post-Last Linvoseltamab Dose, up to 12 weeks | |
Secondary | Incidence of anti-drug antibodies (ADAs) to Linvoseltamab | Phases 1 and 2 | Post-Last Linvoseltamab Dose, up to 30 days | |
Secondary | Titer of ADAs to Linvoseltamab | Phases 1 and 2 | Post-Last Linvoseltamab Dose, up to 30 days | |
Secondary | Objective response rate (ORR) measured using the IMWG criteria | Phase 1 | Up to 5 years | |
Secondary | Duration of Response (DOR) measured using the IMWG criteria | Phase 1 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Progression-free survival (PFS) measured using the IMWG criteria | Phase 1 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria | Phase 1 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Incidence of TEAEs | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Severity of TEAEs | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Incidence of AESIs | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Severity of AESIs | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician | Phase 2 | Up to 5 years | |
Secondary | MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Time to response (TTR) as measured using the IMWG criteria | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | ORR by risk levels | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | MRD-negative rstatus by risk levels | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | DOR by risk levels | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | TTR by risk levels | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | PFS by risk levels | Phase 2 | Post-Last Linvoseltamab Dose, up to 90 days | |
Secondary | Incidence of MRD-negative status | Phase 2 | Up to 5 years | |
Secondary | Cluster of differentiation 34+ (CD34+) stem cell yield | Phase 2 Transplant-eligible cohort | At cycle 4 of induction (each cycle is 28 days long) | |
Secondary | Time to neutrophil engraftment | Phase 2 Transplant-eligible cohort | Up to 100 days post-transplant | |
Secondary | Time to platelet engraftment | Phase 2 Transplant-eligible cohort | Up to 100 days post-transplant | |
Secondary | PFS after ASCT followed by 3 cycles of linvoseltamab | Phase 2 Transplant-eligible cohort | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |